Is PT-141 Right for You? An Evidence-Based Breakdown

PT-141 at a glance:

• Drug class: Melanocortin receptor agonist
• Route: subcutaneous injection
• Typical frequency: as needed before sexual activity (no more than 1 dose/24h, no more than 8/month)
• Half-life: approximately 2.7 hours
• Cash price (US): $300-$1,000/month depending on dose frequency and pharmacy

PT-141 has become one of the more talked-about names in the melanocortin receptor agonist space. The clinical reality is more nuanced than the headlines suggest, and most of what matters fits in a few sentences. PT-141 (bremelanotide) is a synthetic analog of α-MSH that activates melanocortin receptors (MC1R, MC3R, MC4R), producing CNS-mediated effects on sexual arousal.

What is PT-141?

PT-141 (bremelanotide) is a synthetic analog of α-MSH that activates melanocortin receptors (MC1R, MC3R, MC4R), producing CNS-mediated effects on sexual arousal.

There is no single FDA-licensed manufacturer of PT-141 for human therapeutic use. Material in the research and grey markets is supplied by various unregulated sources, which raises real questions about purity and dosing accuracy. PT-141 is not currently approved by the FDA for general human use. Available evidence comes from ongoing clinical trials. We do not endorse self-administration of unapproved compounds.

The drug class melanocortin receptor agonist works by targeting specific receptor pathways. Here's what to expect.

How PT-141 Works in the Body

PT-141 (bremelanotide) is a synthetic analog of α-MSH that activates melanocortin receptors (MC1R, MC3R, MC4R), producing CNS-mediated effects on sexual arousal. The receptor target — compound-specific — drives the downstream effects users care about: improvement in sexual desire and reduction in distress in hsdd trials.

The pharmacokinetics matter for daily use. PT-141 has a half-life of approximately 2.7 hours, which determines how often it is dosed. The standard route of administration is subcutaneous injection, and the typical schedule is as needed before sexual activity (no more than 1 dose/24h, no more than 8/month).

For more detail on the underlying biology, see our breakdown of how PT-141 works.

Who Uses PT-141?

PT-141 is most relevant for people whose situation maps to its approved indications: see Bremelanotide (Vyleesi) — FDA-approved 2019 for hypoactive sexual desire disorder in premenopausal women.

People who should avoid PT-141 include those with the following:

• allergy to the active ingredient or any excipient
• pregnancy or breastfeeding (per label)
• conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of PT-141 include:

• nausea (very common)
• facial flushing
• injection-site reactions
• headache

Serious risks — uncommon but worth knowing — include:

• transient blood pressure increase
• focal hyperpigmentation with frequent use

We have a more detailed breakdown in our PT-141 side-effects guide.

PT-141 vs Alternatives

Other approved HSDD therapies include flibanserin (Addyi). Off-label options include hormonal optimization and behavioral therapy. If you are weighing PT-141 against another option, our comparison pages include What Nobody Tells You About PT-141 Side Effects, PT-141 Results: Realistic Expectations vs. Trial Headlines, Why PT-141 Costs So Much (and 5 Ways to Pay Less).

Bottom Line

PT-141 fits into a broader landscape of melanocortin receptor agonist options. The right choice for any individual depends on insurance, side-effect tolerance, dosing preference, and prescriber familiarity — usually more than on the molecule itself. Multiple randomized controlled trials support its efficacy. If you are considering PT-141, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• What Nobody Tells You About PT-141 Side Effects
• PT-141 Results: Realistic Expectations vs. Trial Headlines
• Why PT-141 Costs So Much (and 5 Ways to Pay Less)
• PT-141 Dosing Patterns in the Research Literature
• hCG: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• What Is Oxytocin? Everything You Should Know Before Starting

Sources

• Skorupskaite K et al. Kisspeptin and Reproduction in Humans. Hum Reprod Update 2014;20:485.
• Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstet Gynecol 2019;134:899.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.